本帖最后由 老马 于 2012-1-13 21:20 编辑 2 j1 S1 j+ F6 Q; `
6 ~' b1 N. d0 d) U
爱必妥和阿瓦斯丁的比较
1 o* d, ?) u! a2 ?
, y( e7 a7 L4 b- ?1 c# I
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 ~. M8 a: s1 `6 D! D& W
6 h- K) P/ Y& S
+ v, z5 t& B9 \% `) L
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 g2 T/ `6 ~9 x6 M9 v5 W2 ~5 |
==================================================
z* P# c% C6 H% \7 V+ f; Q# C; WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* w" ?3 d; }5 APatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ E" r7 Z" Z5 ?- lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ q2 I% x0 W# o- D1 l; k
|
显身卡
# H8 `* o, v0 q4 q% `8 M/ m: d
